📗 Cite This Artifact
Google Ventures (GV)
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Google Ventures (GV)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Google Ventures (GV)</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Mountain View, California, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Corporate Venture Capital (Alphabet)</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2009</td>
</tr>
<tr>
<td class="label">AUM</td>
<td>$8+ billion</td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Life Sciences, AI/ML, Digital Health, Biotechnology</td>
</tr>
<tr>
<td class="label">Parent Company</td>
<td>Alphabet Inc.</td>
</tr>
</table>
Google Ventures (GV)
Overview
...<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Google Ventures (GV)</th>
</tr>
<tr>
<td class="infobox-image" colspan="2">
<em>Google Ventures (GV)</em>
</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Mountain View, California, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Corporate Venture Capital (Alphabet)</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2009</td>
</tr>
<tr>
<td class="label">AUM</td>
<td>$8+ billion</td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Life Sciences, AI/ML, Digital Health, Biotechnology</td>
</tr>
<tr>
<td class="label">Parent Company</td>
<td>Alphabet Inc.</td>
</tr>
</table>
Google Ventures (GV)
Overview
Google Ventures (GV) is the venture capital arm of Alphabet Inc., founded in 2009. As one of the most active corporate venture capital firms globally, GV has made substantial investments in healthcare and life sciences, including a growing portfolio of companies focused on neurodegeneration, Alzheimer's disease, Parkinson's disease, and brain health["@gv2024"]. With over $8 billion in assets under management across multiple funds, GV combines the technical expertise and resources of Alphabet with the agility and focus of a dedicated venture capital firm["@gvportfolio2024"].
GV's distinctive approach leverages Google's technical capabilities—including artificial intelligence, machine learning, data science, and cloud computing—to identify and support companies that are transforming healthcare. This technology-forward perspective has been particularly valuable in the neurodegeneration space, where AI and digital health approaches are enabling new therapeutic modalities and patient monitoring solutions["@ai2020"].
Google Ventures (GV) is the venture capital arm of Alphabet Inc., founded in 2009. As one of the most active corporate venture capital firms, GV has made significant investments in healthcare and life sciences, including a growing portfolio of companies focused on neurodegeneration and brain health["@google2024"]. Based in San Francisco with offices in Boston, New York, London, and Bangalore, GV has invested in over 400 companies since its founding.
The firm's unique position as the venture arm of Alphabet provides access to significant technical resources, including expertise in artificial intelligence, machine learning, cloud computing, and data science. This technological advantage differentiates GV from traditional venture capital firms and enables it to identify opportunities at the intersection of technology and healthcare.
Historical Background and Evolution
Google Ventures was founded in 2009 as Google's corporate venture capital arm, with Bill Maris as its first managing partner. The firm began making investments across various sectors, including healthcare and life sciences, recognizing the potential for technology to transform healthcare delivery and drug development.
In 2013, GV expanded its life sciences focus, hiring David Berry as a general partner to lead healthcare investments. This marked the beginning of GV's systematic approach to investing in biotechnology and medical technology companies. The firm's early investments in companies like Flatiron Health (oncology data) and Foundation Medicine (cancer diagnostics) demonstrated its commitment to applying data science to healthcare challenges.
The 2010s saw GV make several significant investments in neuroscience and neurodegeneration, including investments in Calico (Alphabet's longevity research company), Verily Life Sciences (healthcare AI), and various early-stage biotechnology companies developing treatments for Alzheimer's, Parkinson's, and other neurological disorders.
Investment Strategy
Technology-Forward Approach
GV's investment strategy emphasizes the application of advanced technologies to healthcare challenges[drug2022]:
GV invests across several key areas in neurodegeneration:
Digital Health
Companies developing digital biomarkers, AI-powered diagnostics, and telemedicine platforms for neurological diseases[@digital2023]. GV recognizes the potential of digital health technologies to improve patient monitoring, enable remote clinical trials, and provide early detection of neurodegenerative conditions. The firm has invested in companies developing smartphone-based cognitive assessments, wearable sensors for movement disorder monitoring, and digital platforms for telemedicine in neurology.
Therapeutics
Biotechnology companies developing novel drugs for Alzheimer's, Parkinson's, and other neurodegenerative conditions. GV's investments in this space span various therapeutic modalities, including small molecules, biologics, and gene therapies targeting protein aggregation, neuroinflammation, and other disease mechanisms[@neurobiolaging2022].
Medical Devices
Investment in neuromodulation devices and diagnostic technologies[@neurocomp2023]. GV has backed companies developing devices for deep brain stimulation, transcranial magnetic stimulation, brain-computer interfaces, and neuroprosthetics. These technologies offer potential for treating neurological conditions and restoring function.
Data Science
AI and machine learning companies applying computational approaches to neuroscience research[@npj2023][@drugdisc2023]. GV leverages Alphabet's expertise in AI to identify opportunities where machine learning can accelerate drug discovery, improve diagnostic accuracy, or enable precision medicine approaches.
Therapeutic Area Focus
GV concentrates on several key areas within neurodegeneration[neuro2021]:
Alzheimer's Disease and Related Dementias
- AI-enabled drug discovery for novel therapeutic targets
- Digital biomarkers for early detection and monitoring
- Personalized medicine approaches based on genetic and biomarker data
- Digital therapeutics for cognitive support
Parkinson's Disease
- Wearable and digital monitoring technologies
- AI-based movement analysis and diagnosis
- Novel therapeutic approaches including gene therapy
- Digital health solutions for patient management
Other CNS Disorders
- Epilepsy monitoring and treatment (e.g., NeuroPace)
- Brain-computer interfaces and neurotechnology
- Mood disorders and psychiatric conditions
- Rare neurological diseases
Investment Thesis
GV's investment approach is characterized by:
Technology Leverage
Applying Google's technical expertise to healthcare challenges. GV can draw on Alphabet's extensive technical resources, including machine learning expertise, cloud computing infrastructure, and data science capabilities. This allows GV to evaluate technology-driven opportunities that might be difficult for traditional venture capital firms to assess.
Data-Driven Decision Making
Using analytical capabilities to identify promising opportunities. GV's team includes data scientists and engineers who can evaluate the technical merit of proposed solutions and assess market opportunities using quantitative approaches.
Portfolio Synergy
Creating connections between portfolio companies and Google's ecosystem. GV can facilitate partnerships between portfolio companies and other Alphabet businesses, including Google Cloud, DeepMind, and Verily. This ecosystem approach can provide portfolio companies with access to technology, distribution, and expertise.
Long-Term Vision
Investing in transformative technologies with extended development timelines. GV is willing to invest in companies pursuing ambitious goals that may require many years to achieve, particularly in areas like neurodegeneration where drug development timelines are inherently long.
Portfolio Companies
Calico
Calico is an Alphabet company focused on longevity research and age-related diseases, including neurodegeneration[calico2020]. Founded in 2013, Calico applies advanced technologies to understand the biology of aging and develop interventions that extend healthspan. Key focus areas include:
- Aging Biology: Understanding the fundamental mechanisms of aging
- Therapeutic Development: Creating drugs targeting aging-related pathways
- Neurodegeneration: Specifically addressing Alzheimer's and Parkinson's diseases
- Academic Partnerships: Collaborating with leading research institutions
Calico represents GV's and Alphabet's largest bet on age-related disease research, with partnerships with pharmaceutical companies including AbbVie.
DeepMind Technologies
DeepMind Technologies is an AI company acquired by Google in 2014 that has made revolutionary contributions to biological research[deepmind2021]. While not a traditional investment, DeepMind's work has significant implications for neurodegeneration:
- AlphaFold: Revolutionary protein structure prediction system
- Protein Structure Database: Open-access database of protein structures
- Biological Applications: Applications to understand disease mechanisms
- Neuroscience Research: Direct applications to neuroscience
AlphaFold and its successor AlphaFold 2 have transformed the field of structural biology, enabling researchers to understand protein structures involved in neurodegeneration at unprecedented scale and speed.
Verily Life Sciences
Verily Life Sciences is Alphabet's healthcare research and development organization, focusing on:
- Precision Medicine: Data-driven approaches to health and disease
- Diagnostics: Novel diagnostic technologies and platforms
- Clinical Research: Enabling more efficient clinical trials
- Disease Management: Tools for chronic disease management
NeuroPace
NeuroPace is a medical device company developing responsive neurostimulation systems for epilepsy[device2020]. Founded with support from GV, NeuroPace's RNS System represents a novel approach to treating epilepsy:
- Responsive Stimulation: Delivers electrical stimulation in response to detected seizure activity
- Long-term Monitoring: Continuous EEG monitoring and data collection
- Clinical Evidence: Demonstrated efficacy in reducing seizure frequency
- Expansion Potential: Technology applicable to other neurological conditions
BrainCo
BrainCo is developing brain-computer interface (BCI) technologies with applications in healthcare and human augmentation[neurotech2019]. The company's focus includes:
- Neural Interfaces: Non-invasive brain-computer interfaces
- Healthcare Applications: Monitoring and treatment of neurological conditions
- Human Performance: Applications in attention and cognitive enhancement
- Research Tools: Tools for neuroscience research
Cambridge Cognition
Cambridge Cognition specializes in digital cognitive assessment tools for clinical trials and research:
- Cognitive Testing: Digital platforms for measuring cognitive function
- Clinical Trials: Services for pharmaceutical company clinical trials
- Alzheimer's Research: Tools specifically developed for Alzheimer's disease research
- Regulatory Support: FDA-cleared cognitive assessment instruments
Yumanity Therapeutics
Yumanity Therapeutics (acquired by Prothelia) was developing therapies for neurodegenerative diseases using a novel approach targeting protein misfolding:
- Protein Folding: Targeting mechanisms of protein aggregation
- Novel Targets: Identifying new therapeutic targets in neurodegeneration
- ALS Program: Clinical-stage program for ALS
- Alzheimer's Program: Pipeline for Alzheimer's disease
Other Notable Investments
GV has invested in numerous other companies relevant to neurodegeneration:
- Freenome: AI-enabled blood-based cancer screening
- GRAIL: Early cancer detection through liquid biopsy
- Molecular Templates: Engineered protein therapeutics
- Recursion Pharmaceuticals: AI-enabled drug discovery
- Vicarious Surgical: Surgical robotics
GV has invested in several companies advancing treatments for neurodegenerative diseases:
Calico
Alphabet's company focused on longevity research and age-related diseases, including neurodegeneration[@calico2024][@aging2022][@longevity2023]. Calico (California Life Sciences) was founded in 2013 as a joint venture between Google and AbbVie, with a focus on understanding the biology of aging and developing interventions that could extend healthy lifespan. The company's research spans cellular senescence, proteostasis, and metabolism, with implications for age-related neurodegenerative diseases.
DeepMind Technologies
AI company with significant contributions to protein folding and biological research[@deepmind2024][@nature2023][@alphafold2022]. While not a GV portfolio company per se, DeepMind's AlphaFold system has revolutionized protein structure prediction, with significant implications for drug discovery in neurodegeneration. Understanding protein structures is critical for developing drugs that target proteins involved in Alzheimer's and Parkinson's diseases.
Verily Life Sciences
Healthcare AI and diagnostics company[@verily2024]. Verily develops technologies for disease detection, monitoring, and management, including tools that could benefit patients with neurodegenerative conditions. The company's work in biosensing, population health, and clinical research has applications in neurology.
NeuroPace
Company developing responsive neurostimulation devices for epilepsy. While primarily focused on epilepsy, NeuroPace's technology represents advances in neuromodulation that could have applications in other neurological conditions.
BrainCo
Developing brain-computer interfaces. BrainCo focuses on non-invasive brain-computer interface technology with applications in neurorehabilitation, cognitive enhancement, and neurological disorder management.
Cambridge Cognition
Digital cognitive assessment company. Cambridge Cognition develops digital cognitive testing platforms used in clinical trials and clinical practice, with applications in Alzheimer's disease and other conditions affecting cognition.
Yumanity Therapeutics
Company developing therapies for neurodegenerative diseases (acquired by Prothelia). Yumanity focused on targeting protein misfolding in Alzheimer's, Parkinson's, and ALS.
Other AI/ML Investments
GV has invested in numerous AI-focused healthcare companies, including those developing machine learning models for drug discovery, diagnostic imaging analysis, and clinical decision support.
Impact on Neurodegeneration Research
Google Ventures has impacted the neurodegeneration field through multiple channels[biotech2020]:
Technology Development
- Application of AI and machine learning to drug discovery
- Development of digital biomarkers for patient monitoring
- Advancement of neurotechnology and brain-computer interfaces
- Enable data-driven approaches to clinical development
Capital Deployment
- Provided substantial funding to early-stage neurodegeneration companies
- Supported companies developing novel therapeutic modalities
- Enabled development of digital health solutions for neurological diseases
Strategic Value-Add
- Provided access to Google's technical resources and expertise
- Facilitated partnerships between portfolio companies and Alphabet
- Enabled access to computational infrastructure and talent
- Created networking opportunities within the broader Alphabet ecosystem
Ecosystem Development
- Supported convergence of technology and biotechnology
- Enabled new approaches to clinical trial design and execution
- Advanced the field of digital therapeutics
- Contributed to growth of the digital health sector
Investment Process
GV's investment process combines traditional venture capital due diligence with technology-focused evaluation[drug2022]:
1. Technology Assessment
- Evaluation of technical differentiation and innovation
- Assessment of competitive advantage and defensibility
- Analysis of scalability and platform potential
2. Market Analysis
- Market size and growth projections
- Competitive landscape and positioning
- Regulatory pathway and reimbursement strategy
3. Team Evaluation
- Assessment of founding team and management
- Evaluation of technical and business expertise
- Analysis of ability to execute on vision
4. Strategic Fit
- Alignment with Alphabet/Google strategic interests
- Potential for synergies with other portfolio companies
- Access to technical resources and expertise
5. Value-Add Planning
- Identification of ways GV can provide strategic value
- Planning for technical and operational support
- Integration with Alphabet ecosystem
Strategic Advantages
Technical Expertise
GV leverages Google's deep technical expertise in several areas[ai2021]:
- Artificial Intelligence: Leading AI/ML capabilities for drug discovery and development
- Data Science: Expertise in large-scale data analysis and interpretation
- Cloud Computing: Infrastructure for computational needs
- Engineering: Access to world-class engineering talent
Network Effects
GV portfolio companies benefit from connections to:
- Alphabet companies (Google, DeepMind, Verily)
- Google Cloud customers and partners
- Broader technology ecosystem
- Academic research community
Resources
GV can provide access to:
- Computational infrastructure and tools
- Domain expertise across multiple fields
- Operational support and mentorship
- Follow-on funding for successful companies
Industry Recognition
Google Ventures is recognized as a leading corporate venture capital firm:
- Top Corporate VC: Consistently ranked among leading CVCs
- Healthcare Focus: Recognized for life sciences investment focus
- AI Leadership: Cited for AI/ML applications in healthcare
- Portfolio Success: Multiple successful exits through IPO and acquisition
Collaboration and Partnerships
GV maintains strategic relationships across the healthcare ecosystem:
- Pharmaceutical Companies: Partnerships for drug development
- Academic Institutions: Research collaborations and technology licensing
- Healthcare Systems: Clinical validation and implementation
- Technology Companies: Synergies across the Alphabet ecosystem
Future Directions
GV continues to pursue opportunities in neurodegeneration through:
- Expansion of AI/ML applications in drug discovery
- Investment in digital health and telemedicine
- Support for neurotechnology and brain-computer interfaces
- Exploration of novel therapeutic modalities
The firm remains committed to advancing breakthrough technologies for treating neurodegenerative diseases through strategic investments and active portfolio support.
Capital and Expertise
Providing capital and technical expertise to early-stage companies developing novel therapeutic and diagnostic approaches. GV's investments have enabled companies to pursue ambitious research programs that might not have been possible with traditional venture capital.
AI Acceleration
Applying AI and machine learning to accelerate drug discovery[@ai2022][@ml2023]. GV's involvement in companies like Calico and its AI-focused investments have contributed to the broader application of computational approaches to neurodegeneration drug development.
Digital Health Support
Supporting digital health solutions for patient monitoring and clinical trials[@lancetdigital2023]. GV's investments in digital health companies have enabled development of tools for remote patient monitoring, digital biomarker collection, and decentralized clinical trials.
Technology Partnerships
Facilitating collaborations between technology and biotechnology companies. GV's position within the Alphabet ecosystem has enabled partnerships between traditional biotech and technology companies.
Technical Contributions
GV and its affiliated companies have made significant technical contributions:
AlphaFold
DeepMind's AlphaFold system has transformed protein structure prediction, enabling researchers to predict the structures of proteins implicated in neurodegeneration with unprecedented accuracy[@nature2023][@alphafold2022]. This has significant implications for drug target identification and drug design.
Healthcare AI
Verily's AI research has contributed to developing algorithms for disease detection and monitoring, with potential applications in neurodegenerative disease management.
Digital Biomarkers
Portfolio companies have developed digital biomarkers for Parkinson's disease, Alzheimer's disease, and other conditions, enabling objective measurement of disease progression and treatment response[@digital2023][@wearables2022].
Digital Health Initiatives
GV has been particularly active in digital health:
Remote Monitoring
Investment in companies developing wearable sensors and remote monitoring technologies for neurological conditions[@wearables2022]. These technologies enable continuous monitoring of patients outside clinical settings, providing valuable data for disease management and clinical trials.
Telemedicine
Support for telemedicine platforms that improve access to neurological care[@telepsych2023]. This is particularly important for patients with mobility limitations who may have difficulty accessing specialized care.
Digital Therapeutics
Investment in software-based interventions for neurological conditions. Digital therapeutics offer potential for delivering evidence-based treatments through smartphone applications and other digital platforms.
Clinical Trial Technology
Support for companies developing technology to improve clinical trial efficiency, including electronic data capture, virtual trial platforms, and AI-powered patient recruitment.
AI and Machine Learning Applications
GV's investments have advanced AI applications in neurodegeneration:
Drug Discovery
Machine learning approaches for identifying novel drug candidates and predicting drug-target interactions[@drugdisc2023]. These approaches can accelerate the drug discovery process and reduce development costs.
Diagnostic Imaging
AI algorithms for analyzing neuroimaging data to improve diagnosis of Alzheimer's disease and other conditions[@neuro2023]. These tools can help radiologists detect subtle changes that may be indicative of neurodegeneration.
Clinical Decision Support
Machine learning systems to assist clinicians in treatment decisions, including predicting treatment response and identifying patients at risk for adverse events.
Biomarker Discovery
AI approaches to identifying novel biomarkers for neurodegenerative diseases from large datasets[@biomark2022].
Challenges and Future Directions
GV faces several challenges and opportunities:
Regulatory Pathways
Navigating the regulatory landscape for AI/ML medical devices and digital health products. Regulatory frameworks for these technologies are still evolving.
Clinical Validation
Ensuring that AI/ML tools are clinically validated through rigorous studies. Many digital health products have limited clinical validation.
Integration
Facilitating integration of new technologies with existing healthcare systems. Adoption requires addressing workflow, reimbursement, and interoperability challenges.
Data Privacy
Addressing concerns about data privacy and security in healthcare applications.
Future Investment Directions
GV continues to identify emerging opportunities:
Precision Medicine
Approaches that tailor treatments to individual patients based on genetic, biomarker, and clinical data.
Gene Therapy
Investments in gene therapy technologies for neurological disorders.
Regenerative Medicine
Cell and tissue-based approaches to treating neurodegeneration.
Biomarker Development
Companies developing biomarkers for early diagnosis and treatment response monitoring.
Portfolio Company Categories
GV's neurodegeneration-related investments can be categorized into several groups:
Therapeutics Companies
Companies focused on developing pharmacological interventions for neurodegenerative diseases. These include companies targeting protein aggregation, neuroinflammation, and neuronal survival pathways.
Diagnostics and Monitoring
Companies developing tools for early diagnosis and ongoing monitoring of neurodegenerative conditions. This includes imaging biomarkers, blood-based tests, and digital monitoring tools.
Research Tools
Companies providing tools for neuroscience research, including cell lines, animal models, and computational platforms.
Clinical Trial Infrastructure
Companies developing technology to improve clinical trial design, execution, and analysis.
Ecosystem Integration
GV leverages its position within Alphabet to create ecosystem benefits:
Google Cloud Partnerships
Portfolio companies can access Google Cloud computing resources, including GPU clusters for AI/ML training and secure storage for healthcare data.
DeepMind Collaboration
Select portfolio companies can collaborate with DeepMind on AI applications, leveraging the company's expertise in protein structure prediction and other computational biology challenges.
Verily Partnerships
Opportunities for partnerships with Verily on clinical research, data analytics, and disease management platforms.
Investment Process
GV employs a structured approach to investment:
Sourcing
Deal flow comes from multiple channels, including inbound submissions, referrals from the broader venture community, and proactive outreach to promising companies.
Evaluation
Technical due diligence involves assessment of scientific merit, competitive positioning, and regulatory strategy. GV's team includes former scientists and clinicians who can evaluate complex therapeutic approaches.
Support
Portfolio companies receive ongoing support, including access to Alphabet resources, recruiting assistance, and strategic guidance.
Market Impact
GV's investments have had significant market impact:
Valuation Growth
Many GV healthcare portfolio companies have achieved significant valuation increases, demonstrating investor confidence in their technology and approach.
Public Market Success
Several GV portfolio companies have gone public, providing liquidity for investors and demonstrating the commercial viability of technology-driven healthcare companies.
Acquisitions
Multiple portfolio companies have been acquired by larger pharmaceutical or technology companies, validating the strategic importance of their technologies.
Future Outlook
The future for GV in neurodegeneration looks promising:
Emerging Technologies
Continued advances in AI, gene therapy, and cell therapy create new investment opportunities.
Aging Population
The growing elderly population worldwide increases demand for treatments for neurodegenerative diseases.
Regulatory Evolution
Evolving regulatory frameworks may facilitate approval of novel therapeutic and digital health products.
Conclusion
Google Ventures represents a unique force in neurodegeneration investment, combining venture capital expertise with the technical resources of Alphabet. Through investments in therapeutics, digital health, medical devices, and AI/ML companies, GV has contributed to expanding the pipeline of technologies for addressing Alzheimer's disease, Parkinson's disease, and other neurological conditions.
The firm's distinctive approach—leveraging Google's technical capabilities while maintaining venture capital discipline—positions GV to continue identifying and supporting transformative technologies in the neurodegeneration space. As the understanding of neurodegenerative disease mechanisms advances and new technologies emerge, GV's combination of capital and technical expertise will likely continue to shape the field.
See Also
- [RA Capital Management](/institutions/ra-capital-management)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Digital Health](/mechanisms/digital-health-neurodegeneration)
- [Artificial Intelligence in Neuroscience](/mechanisms/ai-neuroscience)
- [Dementia Discovery Fund](/institutions/dementia-discovery-fund)
- [ARCH Venture Partners](/institutions/arch-venture-partners)
- [Versant Ventures](/institutions/versant-ventures)
External Links
- [Google Ventures Official Website](https://www.gv.com/)
- [GV Portfolio](https://www.gv.com/investments/)
- [Alphabet](https://abc.xyz/)
- [Calico](https://www.calicolabs.com/)
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | institutions-google-ventures |
| kg_node_id | None |
| entity_type | institution |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-d68e9c7ba0fd |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-google-ventures'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-institutions-google-ventures?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Google Ventures (GV)](http://scidex.ai/artifact/wiki-institutions-google-ventures)
http://scidex.ai/artifact/wiki-institutions-google-ventures